April 2022

Department

Research in Review

Highlights from the Community Oncology Alliance (COA) 2022 Community Oncology Conference

04/20/2022

JCP Editors

J Clin Pathways. 2022;8(3):30-32. Addressing Disparities in Cancer Health, Equity, and Outcomes A panel at the 2022 Community Oncology Conference discussed how their programs address disparities in cancer care and access to cancer...

J Clin Pathways....

04/20/2022

Journal of Clinical Pathways

Research in Review

Research in Review Focus on Lung Cancer

04/20/2022

JCP Editors

J Clin Pathways. 2022;8(3):21-23. Therapeutic Targeting of BAP1/ASXL3 Sub-Complex in SCLC Investigators sought to discover the function of the oncogenic BAP1/ASXL3/BRD4 epigenetic axis in small-cell lung cancer (SCLC) by developing a...

J Clin Pathways....

04/20/2022

Journal of Clinical Pathways

Feature

From the Field

Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab

04/20/2022

Erica DiMaria , MD;

David Susman ;

Derek Nay , MD;

Rouslan Kotchetkov , MD, PhD;

Lauren Gerard , MD;

Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.

Dr Kotchetkov and colleagues...

04/20/2022

Journal of Clinical Pathways

Column

Editor's Page

On the Road Again

04/20/2022

Winston Wong , PharmD;

Dr Wong discusses features in this issue, which include insights on ACCC's 48th Annual Meeting & Cancer Business Summit, highlights from COA's Conference, and an article on real-world patterns of B-R administration in patients with iNHL and...

Dr Wong discusses features in...

04/20/2022

Journal of Clinical Pathways

Clinical Pathways GPS

Clinical Pathways: Expanding Beyond Pharmaceuticals

04/20/2022

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Dr Stefanacci explains how changes in our clinical pathways will greatly expand our treatment options, providing significant improvement in both clinical and financial outcomes.

Dr Stefanacci explains how...

04/20/2022

Journal of Clinical Pathways

Trending From ACCC

A Focus on Community Oncology Research

04/20/2022

Association of Community Cancer Centers

ACCC Community Oncology Research Institute (ACORI) works to establish clinical trials as a standard of care in treatment plans and will enable community oncology programs and their multidisciplinary teams to access the tools, knowledge...

ACCC Community Oncology Research...

04/20/2022

Journal of Clinical Pathways

Pharma Insights

Big Data Analytics in Health Care and Drug Therapy Management—Opportunities and Considerations

04/20/2022

Elizabeth Oyekan , PharmD, FCSHP, CPHQ;

Marissa Baker-Wagner , MPH;

Ronaé McLin , MPH;

Dr Okeyan and colleagues discuss key areas where big data analytics are being leveraged in health care, the implications to payer and pharma stakeholders, and key considerations for success.

Dr Okeyan and colleagues ...

04/20/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

April 2022

Department

Feature

Column

Current Issue

Special Reports

Subscribe

April 2022 Volume 8 Issue 3

Specialties

Events

Year Round Education

HMP Global Products